A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy
The purpose of this study is to examine real-world data among participants with stage IIIa melanoma initiating nivolumab as adjuvant treatment in the community practice setting by utilizing patient data from the United States Oncology Network (USON) iKnowMed (iKM) electronic health records (EHR) database.
Melanoma
Time to Treatment Discontinuation (TTD), Up to 39 Months|Recurrence-free Survival (RFS), Up to 39 Months
Number of Participants with Treatment-related Adverse Events (AEs), Up to 39 Months|Time to Next Treatment (TTNT), Up to 39 Months|Number of Participants with Treatment-Related Hospitalizations, Up to 39 Months|Number of Participants with Emergency Department Visits, Up to 39 Months|Overall Survival (OS), Up to 39 Months
The purpose of this study is to examine real-world data among participants with stage IIIa melanoma initiating nivolumab as adjuvant treatment in the community practice setting by utilizing patient data from the United States Oncology Network (USON) iKnowMed (iKM) electronic health records (EHR) database.